Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 72 |
| Updated: | 4/21/2016 |
| Start Date: | October 2015 |
| End Date: | October 2017 |
| Contact: | Mindie H Nguyen, MD, MAS |
| Email: | mindiehn@stanford.edu |
| Phone: | 650-498-5691 |
Safety, Tolerability, and Efficacy of Simeprevir 150 mg Daily Plus Sofosbuvir 400 mg Daily for 24 Weeks in Patients With Chronic Hepatitis C Genotype 1 With CPT Score of 6 or Lower Who Are IFN-Intolerant or Unwilling to be Treated With IFN
The goal of this pilot study is to examine both efficacy and tolerability in patients with
HCV genotype 1 and mild decompensation with Child-Pugh-Turcott score of 6 or lower. The CPT
score is used to assess the prognosis of chronic liver diseases, as well as the required
strength and treatment and necessity of liver transplantation. A higher CPT score denotes
higher necessity of liver transplantation.
HCV genotype 1 and mild decompensation with Child-Pugh-Turcott score of 6 or lower. The CPT
score is used to assess the prognosis of chronic liver diseases, as well as the required
strength and treatment and necessity of liver transplantation. A higher CPT score denotes
higher necessity of liver transplantation.
Key objectives of this study include:
1. To describe efficacy (SVR) in a special population of patients with chronic hepatitis C
who are not willing or not candidates for IFN-based therapy.
2. To describe safety, tolerability, and treatment persistency in this patient population
with advanced liver disease.
1. To describe efficacy (SVR) in a special population of patients with chronic hepatitis C
who are not willing or not candidates for IFN-based therapy.
2. To describe safety, tolerability, and treatment persistency in this patient population
with advanced liver disease.
Inclusion criteria:
1. Adult 18-72 years
2. Cirrhosis: defined by stage 4 on biopsy or noninvasive tests or presence of
splenomegaly and platelet of 130K or lower, or presence of shrunken nodular liver on
CT or MRI, or presence of varices or encephalopathy or ascites.
3. HCV genotype 1 or indeterminate and later assessed at Screening and confirmed as
genotype 1
Exclusion criteria:
1. Uncontrolled ascites, uncontrolled hepatic encephalopathy, or uncontrolled
esophageal/gastric varices
2. Co-infection with HIV or hepatitis B (HBV)
3. CPT 7 or above, or MELD >10
4. Total bilirubin 4.0 mg/dL or above
5. CrCl (creatinine clearance) < 30 mL/min
6. Any unstable active medical illnesses.
7. Active use of illicit substances, alcohol, or smoking.
8. Any malignancy within last 5 years except for basal cell skin cancer that has been
adequately treated or HCC within Milan or UCSF criteria, which will be acceptable
9. Any prior treatment with direct acting antivirals (approved or investigational),
including HCV protease inhibitors, such as SMV. Patients who received prior treatment
with SOF, and/or NS5A inhibitors (e.g. ledipasvir or Daclatasvir) can be included in
this study
10. Platelet < 30 K/uL
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials